FDA
-
-
-
-
-
-
-
Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or
-
-
-
-
-
-
-
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2020
-
-
-
-
-
-
-
Calyxt Issues Stockholder Letter
-
-
-
-
-
-
-
Cellectis Reports Financial Results for Second Quarter and First Six Months 2019
-
-
-
-
-
-
-
Calyxt Reports 4th Quarter and Full Year 2018 Financial Results
-
-
-
-
-
-
-
Calyxt Reports Financial Results for Second Quarter and Half-Year 2018
-
-
-
-
-
-
-
Cellectis Files IND for UCART22 in Acute Lymphoblastic Leukemia (B-ALL)
-
251,637 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All